Pharmacokinetic drug-drug interaction and their implication in clinical management

Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%. In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy. DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic. In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 2012, and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications.

[1]  R. Kapil,et al.  Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. , 2012, Clinical drug investigation.

[2]  T. Macgregor,et al.  Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers , 2011, Journal of clinical pharmacology.

[3]  R. Royer,et al.  ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY , 1985, The Lancet.

[4]  S. Naty,et al.  Clarithromycin in the Treatment of Legionella pneumophila Pneumonia Associated with Multiorgan Failure in a Previously Healthy Patient , 2005, Clinical drug investigation.

[5]  A. Amdisen.  Lithium and Drug Interactions , 1982, Drugs.

[6]  A. Somogyi,et al.  Pharmacokinetic Interactions of Cimetidine 1987 , 1987, Clinical pharmacokinetics.

[7]  J. Beijnen,et al.  Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.

[8]  M. Døssing,et al.  Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism , 2004, European Journal of Clinical Pharmacology.

[9]  M. Postelnick,et al.  The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. , 2000, Archives of internal medicine.

[10]  J. Handler.  Lithium and Antihypertensive Medication: A Potentially Dangerous Interaction , 2009, Journal of clinical hypertension.

[11]  Silverman Ja,et al.  Regulation and function of the multidrug resistance genes in liver. , 1995 .

[12]  G. De Sarro,et al.  Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy. , 2003, Pharmacological research.

[13]  J. Fleishaker,et al.  Gender does not affect the degree of induction of tirilazad clearance by phenobarbital , 1996, European Journal of Clinical Pharmacology.

[14]  G. Trifirò,et al.  Preventing drug interactions with antidepressants in the elderly , 2007 .

[15]  H. Krum,et al.  Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class , 2003, Drug safety.

[16]  A. Li,et al.  Overview: pharmacokinetic drug-drug interactions. , 1997, Advances in pharmacology.

[17]  J. S. Lee,et al.  Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin , 2004, European Journal of Clinical Pharmacology.

[18]  M. Murray,et al.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[19]  A. Kandus,et al.  Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. , 1994, Transplantation proceedings.

[20]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[21]  P. Neuvonen,et al.  Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin , 1996, Epilepsia.

[22]  C. Shim,et al.  Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats. , 2000, Research communications in molecular pathology and pharmacology.

[23]  G. De Sarro,et al.  Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes , 2010, European Journal of Clinical Pharmacology.

[24]  P. Ward,et al.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[25]  S. Webber,et al.  Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[26]  A. Gasbarrini,et al.  Use and indications of cholestyramine and bile acid sequestrants , 2013, Internal and Emergency Medicine.

[27]  H. Yamazaki,et al.  A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[28]  H. Echizen,et al.  Clinically Significant Drug Interactions with Antacids , 2011, Drugs.

[29]  S. Bates,et al.  Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. , 2011, Cancer research.

[30]  S. Thorgeirsson,et al.  Regulation and function of the multidrug resistance genes in liver. , 1995, Progress in liver diseases.

[31]  M. Ua.  Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. , 1996 .

[32]  H. Kusuhara,et al.  Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney , 2012, Journal of Pharmacology and Experimental Therapeutics.

[33]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[34]  M. Fromm,et al.  The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Jerry H Gurwitz,et al.  Healthy aging , 1997, BMJ.

[36]  D. Urbach,et al.  Effect of metoclopramide on digoxin absorption from tablets and capsules , 1984, Clinical pharmacology and therapeutics.

[37]  G. Sudlow,et al.  The characterization of two specific drug binding sites on human serum albumin. , 1975, Molecular pharmacology.

[38]  A. Pozzi,et al.  Pain management for dentists: the role of ibuprofen. , 2011, Annali di stomatologia.

[39]  D. Trenk,et al.  Drug interaction between propafenone and metoprolol. , 1987, British journal of clinical pharmacology.

[40]  G. De Sarro,et al.  Antiepileptic drugs for central post-stroke pain management. , 2012, Pharmacological research.

[41]  K. Johnell,et al.  The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly , 2007, Drug safety.

[42]  R. Morris,et al.  Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. , 2003, British journal of clinical pharmacology.

[43]  B. Dupuis,et al.  Analysis of the direct cost of adverse drug reactions in hospitalised patients , 2001, European Journal of Clinical Pharmacology.

[44]  K. Venkatesan.  Pharmacokinetic Drug Interactions with Rifampicin , 1992, Clinical pharmacokinetics.

[45]  L. Gallelli,et al.  Phenobarbital/Lamotrigine Coadministration–Induced Blood Dyscrasia in a Patient with Epilepsy , 2010, The Annals of pharmacotherapy.

[46]  Pär Matsson,et al.  Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.

[47]  C. Campañá,et al.  Clinically Significant Drug Interactions with Cyclosporin An Update , 1996, Clinical pharmacokinetics.

[48]  K. S. Dalal,et al.  Gastrointestinal medications. , 2015, Nursing.

[49]  M. Mercuri,et al.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. , 1999, The American journal of cardiology.

[50]  U. Specht,et al.  Pharmacokinetic Interactions of the New Antiepileptic Drugs , 1996, Clinical pharmacokinetics.

[51]  M B Kristensen,et al.  Drug Interactions and Clinical Pharmacokinetics , 1976, Clinical pharmacokinetics.

[52]  R. Morris,et al.  Diltiazem does not always increase blood cyclosporin concentration. , 1996, British journal of clinical pharmacology.

[53]  L. Gallelli,et al.  Role of CYP3A5 in Abnormal Clearance of Methadone , 2008, The Annals of pharmacotherapy.

[54]  F. Guengerich.  Characterization of human cytochrome P450 enzymes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  W. A. Phillips,et al.  Effects of colestipol hydrochloride on drug absorption in the rat II. , 1976, Journal of pharmaceutical sciences.

[56]  U. Meyer,et al.  Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. , 1996, The Yale journal of biology and medicine.

[57]  U. Fagerholm.  Prediction of human pharmacokinetics — renal metabolic and excretion clearance , 2007, The Journal of pharmacy and pharmacology.

[58]  Ute Hofmann,et al.  Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs) , 2011, PloS one.

[59]  M. Bokor-Bratić,et al.  [Clinical use of tetracyclines in the treatment of periodontal diseases]. , 2000, Medicinski pregled.

[60]  M. Fromm,et al.  Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.

[61]  M. Murray.  DRUG‐MEDIATED INACTIVATION OF CYTOCHROME P450 , 1997, Clinical and experimental pharmacology & physiology.

[62]  M. Liu,et al.  Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. , 2010, Clinical therapeutics.

[63]  S. Corrao,et al.  Interaction Risk with Proton Pump Inhibitors in General Practice: Significant Disagreement between Different Drug-Related Information Sources , 2006 .

[64]  G. De Sarro,et al.  Rosuvastatin-induced Rhabdomyolysis Probably via CYP2C9 Saturation , 2009, Drug metabolism and drug interactions.

[65]  S. Gelone,et al.  Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus , 2007, Pharmacotherapy.

[66]  J. Markowitz,et al.  Interactions Between Antipsychotic and Antihypertensive Drugs , 1995, The Annals of pharmacotherapy.

[67]  J. Houston,et al.  Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. , 1996, British journal of clinical pharmacology.

[68]  G. De Sarro,et al.  Effects of Carbamazepine/Oxycodone Coadministration in the Treatment of Trigeminal Neuralgia , 2011, The Annals of pharmacotherapy.

[69]  S. Mueller,et al.  Pharmacokinetic drug-drug interactions between calcineurin inhibitors and proliferation signal inhibitors with anti-microbial agents: implications for therapeutic drug monitoring. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[70]  A. Li,et al.  Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. , 1997, Chemico-biological interactions.

[71]  S. Preskorn,et al.  Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. , 1994, Journal of clinical psychopharmacology.

[72]  M. Bunker,et al.  Clinically significant drug interactions with antituberculosis agents , 1997 .

[73]  M. Ferraro,et al.  Retrospective Evaluation of Adverse Drug Reactions Induced by Nonsteroidal Anti-Inflammatory Drugs , 2007, Clinical drug investigation.

[74]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[75]  J. Houston,et al.  Effect of Omeprazole on Diazepam Disposition in the Rat: in Vitro and in Vivo Studies , 1995, Pharmaceutical Research.

[76]  G. Bocci,et al.  Drug therapeutic failures in emergency department patients. A university hospital experience. , 2004, Pharmacological research.

[77]  J. Peris,et al.  Pharmacokinetic Interaction Between High‐Dose Methotrexate and Amoxycillin , 1993, Therapeutic drug monitoring.

[78]  H. Echizen,et al.  Drug-Drug Interaction Profiles of Proton Pump Inhibitors , 2010, Clinical pharmacokinetics.

[79]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[80]  G. De Sarro,et al.  Adverse drug reactions to antibiotics observed in two pulmonology divisions of catanzaro, Italy: a six-year retrospective study. , 2002, Pharmacological research.

[81]  G. Alí,et al.  Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. , 2011, Neoplasia.

[82]  G. Muirhead,et al.  Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. , 2000, British journal of clinical pharmacology.

[83]  E. Mini,et al.  Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.

[84]  G. De Sarro,et al.  Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. , 2007, Archives of gerontology and geriatrics.

[85]  R. Savino,et al.  Characteristics and Clinical Implications of the Pharmacokinetic Profile of Ibuprofen in Patients with Knee Osteoarthritis , 2012, Clinical Drug Investigation.

[86]  R. Levy.  Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.

[87]  Dominique Mottier,et al.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. , 2008, Journal of the American College of Cardiology.

[88]  S. Piscitelli,et al.  The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer , 1994, Cancer.

[89]  L. Gallelli,et al.  Venlafaxine–Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation , 2008, The Annals of pharmacotherapy.

[90]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[91]  A. Somogyi,et al.  Drug Interactions with Cimetidine , 1982, Clinical pharmacokinetics.

[92]  D W Nebert,et al.  The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. , 1991, DNA and cell biology.

[93]  P. Agarwal,et al.  Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics , 2010, Drug metabolism and drug interactions.

[94]  H. Bussey,et al.  A Review of Enzyme Induction of Warfarin Metabolism with Recommendations for Patient Management , 1997, Pharmacotherapy.

[95]  M. Otagiri,et al.  Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. , 2002, Biological & pharmaceutical bulletin.

[96]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.